If you miss an appointment to receive your canakinumab dose, contact your healthcare provider as soon as you remember to reschedule. It is important to try and remember all of your appointments while receiving this medicine.
How Does It Work?
Canakinumab is a manufactured antibody (a protein normally produced by the immune system). It works by blocking the actions of interleukin-1 beta (IL-1β), a protein that causes inflammation in the body. People with CAPS or SJIA have increased levels of IL-1β. By blocking its action, canakinumab reduces the inflammation and symptoms associated with CAPS or SJIA.
In a clinical study, canakinumab was shown to reduce symptoms of CAPS. In the study, 97 percent of people had minimal symptoms or improved symptoms after eight weeks of treatment. No one in the study experienced a flare-up of symptoms over eight months of treatment.
In clinical studies of canakinumab for SJIA, children or adolescents given canakinumab had symptom reduction, as well as a better chance to decrease or eliminate their corticosteroids, compared to a placebo (an injection with no active ingredients).
Written by/reviewed by: Kristi Monson, PharmD;Arthur Schoenstadt, MD
Last reviewed by: KristiMonson, PharmD;
List of references (click here):
Ilaris [package insert]. East Hanover, NJ: Novartis Pharmaceuticals Corporation;2013 May.
Food and Drug Administration Web site. Vaccines, Blood and Biologics, Resources for Healthcare Providers. Available at: http://www.fda.gov/BiologicsBloodVaccines/ResourcesforYou/HealthcareProviders/default.htm. Accessed September 30, 2011.
eMedTV serves only as an informational resource. This site does not dispense medical advice or advice of any kind.
Site users seeking medical advice about their specific situation should consult with their own physician. Click